Additional Relevant Details NsGene will receive funding from Takeda for technology development that enables NsGene to complete critical scientific milestones needed for clinical trials and further constructive partnering. Further details of the agreement were not disclosed. Takeda is considering regenerative medicine as a potential new modality to treat diseases and is committed to supporting such research. The research collaboration with NsGene marks one of Takeda’s efforts to explore a novel biologics modality and implantable drug delivery system that could potentially make an impact in the lives of many patients.